Amarin Plummets After Patent Appeal Shows Key Drug Sales at Risk
- Stock plunged as much as 31% after hearing raised concerns
- Amarin seen as unlikely to win appeal for key drug patents
This article is for subscribers only.
Amarin Corp. fell the most since March after it faced tough questioning from a U.S. appeals court reviewing the validity of patents on its only product, the heart treatment Vascepa.
The three-judge panel of the U.S. Court of Appeals for the Federal Circuit had no questions at argument Wednesday for the defendants, generic-drug makers Hikma Pharmaceuticals Plc and Dr. Reddy’s Laboratories Ltd.